
  
    
      
        Background_NNP
        Among_IN the_DT 11_CD cancer_NN registries_NNS that_WDT contract_NN with_IN the_DT
        Surveillance_NNP ,_, Epidemiology_NNP ,_, and_CC End_NN Results_NNS (_( SEER_NNP )_) Program_NN
        of_IN the_DT US_NNP National_NNP Cancer_NNP Institute_NNP ,_, the_DT Utah_NNP Cancer_NNP
        Registry_NNP reports_VBZ the_DT lowest_JJS overall_JJ incidence_NN of_IN cancer_NN ._.
        During_IN the_DT years_NNS 1995_CD -_: 1999_CD ,_, age-adjusted_JJ (_( to_TO the_DT 2000_CD US_NNP
        population_NN )_) invasive_JJ cancer_NN incidence_NN rates_NNS in_IN white_JJ men_NNS
        for_IN the_DT leading_VBG 10_CD sites_NNS ,_, per_IN 100_CD ,_, 000_CD person-years_JJ ,_, were_VBD
        393_CD ._. 1_LS in_IN Utah_NNP compared_VBD with_IN 451_CD ._. 0_CD in_IN SEER_NNP (_( without_IN Utah_NNP )_) [_NN
        1_CD ]_NN ._. Lower_JJR rates_NNS in_IN Utah_NNP were_VBD observed_VBN for_IN all_DT sites_NNS
        except_IN prostate_NN cancer_NN and_CC melanoma_NN of_IN the_DT skin_NN (_( 174_CD ._. 5_LS vs_NNS ._.
        157_CD ._. 8_CD for_IN prostate_NN ,_, 42_CD ._. 7_CD vs_NNS ._. 81_CD ._. 9_CD for_IN lung_NN and_CC bronchus_JJ ,_,
        48_CD ._. 8_CD vs_NNS ._. 63_CD ._. 9_CD for_IN colon_NN and_CC rectum_NN ,_, 31_CD ._. 7_CD vs_NNS ._. 38_CD ._. 8_CD for_IN
        urinary_JJ bladder_NN ,_, 22_CD ._. 4_LS vs_NNS ._. 24_CD ._. 6_CD for_IN non-_NN Hodgkin_NNP 's_POS lymphoma_NN ,_,
        25_CD ._. 3_LS vs_NNS ._. 23_CD ._. 4_LS for_IN melanoma_NN of_IN the_DT skin_NN ,_, 13_CD ._. 0_CD vs_NNS ._. 16_CD ._. 3_LS for_IN
        oral_JJ cavity_NN and_CC pharynx_NN ,_, 11_CD ._. 0_CD vs_NNS ._. 15_CD ._. 5_LS for_IN kidney_NN and_CC renal_JJ
        pelvis_NNS ,_, 13_CD ._. 9_CD vs_NNS ._. 16_CD ._. 7_CD for_IN leukemia_NN ,_, and_CC 9_CD ._. 9_CD vs_NNS ._. 12_CD ._. 2_LS for_IN
        pancreas_NN )_) ._. Comparatively_NNP high_JJ prostate_NN cancer_NN incidence_NN
        rates_NNS in_IN the_DT 1990_CD s_VBZ among_IN white_JJ men_NNS in_IN Utah_NNP have_VBP been_VBN
        reported_VBN previously_RB [_NN 2_CD 3_CD ]_NN ._.
        In_IN 1847_CD ,_, members_NNS of_IN the_DT Church_NNP of_IN Jesus_NNP Christ_NNP of_IN
        Latter-day_NNP Saints_NNP (_( LDS_NNP or_CC Mormon_NNP )_) settled_VBD the_DT Salt_NNP Lake_NNP
        Valley_NNP in_IN northern_JJ Utah_NNP [_NN 4_CD ]_NN ._. Over_IN the_DT next_JJ several_JJ
        years_NNS ,_, LDS_NNP Church_NNP members_NNS settled_VBN over_IN 350_CD communities_NNS
        throughout_IN the_DT territory_NN ._. Today_NN ,_, about_IN 70_CD %_NN of_IN Utah_NNP 's_POS 2_CD ._. 2_CD
        million_CD population_NN is_VBZ affiliated_VBN with_IN the_DT LDS_NNP Church_NNP [_NN 5_CD 6_CD
        ]_NN ._. Over_IN 85_CD %_NN of_IN the_DT state_NN 's_POS population_NN is_VBZ white_JJ ,_,
        non-_NN Hispanic_JJ [_NN 6_CD ]_NN ._. Low_NNP cigarette-smoking_JJ and_CC
        alcohol-drinking_JJ prevalence_NN observed_VBD among_IN LDS_NNP helps_VBZ
        explain_VB the_DT comparatively_RB low_JJ rates_NNS for_IN many_JJ of_IN these_DT
        cancer_NN sites_NNS in_IN Utah_NNP [_NN 5_CD ]_NN ._. Whether_IN the_DT high_JJ prostate_NN
        cancer_NN incidence_NN rates_NNS reflect_VBP higher_JJR rates_NNS among_IN LDS_NNP is_VBZ
        unclear_JJ ._.
        We_PRP linked_VBD electronic_JJ records_NNS from_IN the_DT LDS_NNP Church_NNP
        membership_NN files_NNS and_CC the_DT Utah_NNP Cancer_NNP Registry_NNP to_TO examine_VB
        the_DT magnitude_NN and_CC temporal_JJ trends_NNS in_IN prostate_NN cancer_NN
        incidence_NN rates_NNS among_IN LDS_NNP and_CC nonLDS_NN residents_NNS of_IN Utah_NNP for_IN
        the_DT calendar_NN years_NNS 1985_CD through_IN 1999_CD ._. Cases_NNS judged_VBN to_TO have_VB
        been_VBN incidentally_RB detected_VBN through_IN transurethral_NN resection_NN
        of_IN the_DT prostate_NN (_( TURP_NNP )_) ,_, a_DT procedure_NN typically_RB used_VBD to_TO treat_VB
        obstructive_JJ uropathy_NN ,_, were_VBD also_RB identified_VBN and_CC considered_VBN
        in_IN the_DT rate_NN calculations_NNS to_TO provide_VB a_DT clearer_JJR indication_NN of_IN
        the_DT effect_NN of_IN screening_NN on_IN the_DT incidence_NN rates_NNS of_IN prostate_NN
        cancer_NN ._. We_PRP also_RB examined_VBD results_NNS from_IN a_DT statewide_JJ health_NN
        survey_NN to_TO characterize_VB prostate-specific_JJ antigen_NN screening_NN
        patterns_NNS by_IN religious_JJ affiliation_NN ._.
      
      
        Methods_NNP
        
          Utah_NNP Cancer_NNP Registry_NNP
          The_DT population-based_JJ Utah_NNP Cancer_NNP Registry_NNP (_( UCR_NNP )_) was_VBD
          established_VBN in_IN 1966_CD and_CC has_VBZ continuously_RB participated_VBN in_IN
          the_DT National_NNP Cancer_NNP Institute_NNP 's_POS Surveillance_NNP ,_,
          Epidemiology_NNP ,_, and_CC End_NN Results_NNS (_( SEER_NNP )_) program_NN since_IN 1973_CD ._.
          UCR_NNP staff_NN members_NNS and_CC local_JJ cancer_NN registrars_NNS identify_VBP
          incident_NN cases_NNS of_IN cancer_NN among_IN Utah_NNP residents_NNS through_IN
          routine_JJ and_CC systematic_JJ review_NN of_IN pathology_NN reports_NNS ,_,
          medical_JJ records_NNS ,_, radiation_NN therapy_NN records_NNS ,_, hospital_NN
          discharge_NN lists_NNS ,_, and_CC vital_JJ records_NNS ._. Tumor_NNP characteristics_NNS
          including_VBG histology_NN ,_, grade_NN ,_, and_CC primary_JJ site_NN are_VBP coded_VBN
          according_VBG to_TO the_DT International_NNP Classification_NNP of_IN Disease_NNP
          for_IN Oncology-_NNP Second_NNP Edition_NNP (_( ICDO-_NNP 2_LS )_) [_NN 7_CD ]_NN ._. Categories_NNP
          of_IN stage_NN of_IN disease_NN at_IN diagnosis_NN are_VBP documented_VBN in_IN the_DT
          Summary_NNP Staging_NNP Guide_NNP of_IN the_DT SEER_NNP program_NN of_IN the_DT National_NNP
          Cancer_NNP Institute_NNP [_NN 8_CD ]_NN ._. Registry_NNP records_NNS also_RB include_VBP
          information_NN regarding_VBG treatment_NN and_CC patient_NN
          characteristics_NNS such_JJ as_IN age_NN at_IN diagnosis_NN ,_, gender_NN ,_,
          race_NN /_NN ethnicity_NN ,_, and_CC place_NN of_IN residence_NN at_IN diagnosis_NN ._.
          Information_NNP regarding_VBG patient_NN characteristics_NNS ,_, cancer_NN
          diagnosis_NN ,_, and_CC treatment_NN is_VBZ ascertained_JJ from_IN specific_JJ
          statements_NNS in_IN medical_JJ records_NNS ,_, reports_NNS from_IN private_JJ
          pathology_NN laboratories_NNS and_CC radiotherapy_NN units_NNS ,_, and_CC death_NN
          certificates_NNS ._. Cancer_NN surveillance_NN in_IN Utah_NNP is_VBZ conducted_VBN in_IN
          accordance_NN with_IN standards_NNS instituted_VBN by_IN the_DT SEER_NNP program_NN
          and_CC the_DT North_JJ American_NNP Association_NNP of_IN Central_NNP Cancer_NNP
          Registries_NNP [_NN 9_CD 10_CD ]_NN ._.
        
        
          Linkage_NNP of_IN cancer_NN data_NNS with_IN LDS_NNP church_NN
          records_NNS
          UCR_NNP records_NNS were_VBD linked_VBN to_TO LDS_NNP Church_NNP membership_NN
          records_NNS to_TO determine_VB membership_NN in_IN the_DT LDS_NNP Church_NNP ._. The_DT
          linkage_NN process_NN took_VBD place_NN under_IN direct_JJ supervision_NN of_IN
          the_DT Church_NNP and_CC the_DT UCR_NNP and_CC was_VBD conducted_VBN in_IN the_DT Church_NNP 's_POS
          Member_NNP and_CC Statistical_NNP Records_NNPS Department_NNP ._.
          Confidentiality_NNP of_IN record_NN information_NN was_VBD strictly_RB
          enforced_VBN ._. After_IN the_DT records_NNS were_VBD linked_VBN ,_, all_DT personal_JJ
          identifying_VBG information_NN was_VBD stripped_VBN from_IN the_DT
          database_NN ._.
          Records_NNPS were_VBD linked_VBN using_VBG the_DT probabilistic_JJ linking_VBG
          program_NN LinkPro_NNP [_NN 11_CD ]_NN ._. The_DT program_NN calculates_VBZ
          probabilities_NNS to_TO identify_VB whether_IN a_DT pair_NN of_IN records_NNS
          refers_VBZ to_TO the_DT same_JJ person_NN ._. Ten_CD variables_NNS that_WDT were_VBD common_JJ
          to_TO both_DT sets_NNS of_IN records_NNS were_VBD used_VBN to_TO link_VB the_DT records_NNS :_:
          first_JJ ,_, middle_JJ ,_, and_CC last_JJ names_NNS ;_: birth_NN day_NN ;_: birth_NN month_NN ;_:
          birth_NN year_NN ;_: gender_NN ;_: zip_NN code_NN ;_: vital_JJ status_NN ;_: and_CC maiden_JJ
          name_NN ._. SOUNDEX_NNP versions_NNS of_IN the_DT names_NNS were_VBD used_VBN in_IN the_DT
          matching_VBG process_NN ,_, while_IN actual_JJ names_NNS were_VBD used_VBN in_IN the_DT
          review_NN process_NN ._.
          There_EX were_VBD 121_CD ,_, 967_CD incident_NN cases_NNS of_IN cancer_NN identified_VBN
          in_IN the_DT UCR_NNP database_NN from_IN 1973_CD to_TO 2000_CD and_CC approximately_RB
          6_CD ._. 6_CD million_CD records_NNS in_IN the_DT LDS_NNP Church_NNP database_NN ._. Records_NNPS
          were_VBD linked_VBN in_IN three_CD stages_NNS ._. The_DT first_JJ stage_NN linked_VBD all_DT
          records_NNS that_WDT matched_VBD exactly_RB on_IN first_JJ ,_, middle_JJ ,_, and_CC last_JJ
          names_NNS ;_: complete_JJ birth_NN date_NN ;_: and_CC gender_NN ._. There_EX were_VBD 36_CD ,_, 187_CD
          such_JJ records_NNS declared_VBD matches_VBZ without_IN review_NN ._. The_DT second_JJ
          stage_NN consisted_VBD of_IN taking_VBG the_DT remaining_VBG records_NNS and_CC
          forcing_VBG them_PRP to_TO link_VB on_IN last_JJ name_NN and_CC at_IN least_JJS five_CD
          additional_JJ variables_NNS ._. The_DT 6_CD ,_, 652_CD records_NNS that_WDT linked_VBD on_IN
          eight_CD additional_JJ variables_NNS were_VBD declared_VBN matches_VBZ without_IN
          review_NN ._. Of_IN the_DT 18_CD ,_, 587_CD records_NNS that_WDT linked_VBD on_IN seven_CD
          additional_JJ variables_NNS ,_, 17_CD ,_, 612_CD were_VBD declared_VBN matches_VBZ
          without_IN review_NN ,_, and_CC 975_CD were_VBD reviewed_VBN with_IN 859_CD declared_VBD
          matches_NNS ._. Of_IN the_DT 21_CD ,_, 146_CD records_NNS that_WDT linked_VBD on_IN six_CD
          additional_JJ variables_NNS ,_, 14_CD ,_, 378_CD were_VBD declared_VBN matches_VBZ
          without_IN review_NN ,_, and_CC 6_CD ,_, 768_CD were_VBD reviewed_VBN of_IN which_WDT 2_CD ,_, 812_CD
          were_VBD declared_VBN matches_NNS ._. Finally_RB ,_, of_IN the_DT 22_CD ,_, 492_CD records_NNS
          that_WDT matched_VBD on_IN five_CD additional_JJ variables_NNS ,_, 1_CD ,_, 650_CD were_VBD
          declared_VBN matches_VBZ without_IN review_NN ,_, 5_CD ,_, 629_CD were_VBD reviewed_VBN with_IN
          1_CD ,_, 328_CD declared_VBD matches_VBZ ,_, and_CC 15_CD ,_, 213_CD were_VBD declared_VBN
          non-matches_JJ without_IN review_NN ._. The_DT third_JJ stage_NN of_IN the_DT
          linkage_NN process_NN consisted_VBD of_IN taking_VBG the_DT remaining_VBG
          unlinked_JJ records_NNS and_CC forcing_VBG them_PRP to_TO link_VB on_IN first_JJ name_NN
          and_CC at_IN least_JJS six_CD other_JJ additional_JJ variables_NNS ._. There_EX were_VBD
          3_CD ,_, 338_CD such_JJ records_NNS ._. All_DT were_VBD reviewed_VBN ,_, with_IN 380_CD declared_VBD
          matches_NNS ._. These_DT stages_NNS resulted_VBD in_IN 81_CD ,_, 617_CD (_( 68_CD %_NN )_) of_IN the_DT UCR_NNP
          records_NNS being_VBG linked_VBN to_TO a_DT Church_NNP record_NN ._.
        
        
          Data_NNP
          All_DT incident_NN cases_NNS of_IN prostate_NN cancer_NN (_( ICDO-_NNP 2_CD site_NN
          code_NN C_NNP 61_CD ._. 9_CD )_) that_WDT were_VBD diagnosed_VBN among_IN Utah_NNP residents_NNS
          during_IN the_DT time_NN period_NN 1985_CD -_: 99_CD were_VBD identified_VBN from_IN
          records_NNS of_IN the_DT Utah_NNP Cancer_NNP Registry_NNP ._. Lymphomas_NNP of_IN the_DT
          prostate_NN (_( ICDO-_NNP 2_CD histologies_NNS 9590_CD -_: 9989_CD )_) were_VBD excluded_VBN
          from_IN the_DT study_NN ._. Analyses_NNS were_VBD further_RBR restricted_VBN to_TO
          histologically_RB confirmed_VBD cases_NNS that_WDT were_VBD 50_CD years_NNS and_CC
          older_JJR at_IN the_DT time_NN of_IN prostate_NN cancer_NN diagnosis_NN ._. Stage_NN
          categories_NNS of_IN disease_NN at_IN diagnosis_NN were_VBD local_JJ /_NN regional_JJ ,_,
          distant_JJ ,_, and_CC unstaged_JJ ._. Local_JJ and_CC regional_JJ stages_NNS were_VBD
          combined_VBN because_IN of_IN the_DT large_JJ proportion_NN of_IN cases_NNS
          upsataged_JJ because_IN of_IN surgery_NN [_NN 12_CD ]_NN ._.
        
        
          TURP_NNP and_CC Incidental_NNP Detection_NNP
          Although_IN the_DT UCR_NNP has_VBZ historically_RB collected_VBN surgery_NN
          information_NN on_IN cancer_NN cases_NNS ,_, including_VBG whether_IN a_DT prostate_NN
          cancer_NN case_NN underwent_VBD a_DT TURP_NNP ,_, not_RB until_IN 1998_CD did_VBD they_PRP
          identify_VBP whether_IN the_DT TURP_NNP led_VBD to_TO or_CC was_VBD the_DT result_NN of_IN a_DT
          prostate_NN cancer_NN diagnosis_NN ._. This_DT change_NN in_IN the_DT level_NN of_IN
          information_NN collected_VBN was_VBD made_VBN among_IN all_PDT the_DT registries_NNS
          participating_VBG in_IN the_DT SEER_NNP program_NN ._. In_IN the_DT UCR_NNP during_IN
          1998_CD -_: 99_CD ,_, the_DT proportion_NN of_IN TURPs_NNP performed_VBD among_IN cases_NNS
          resulting_VBG in_IN an_DT incidental_JJ finding_NN because_IN of_IN the_DT surgery_NN
          for_IN benign_JJ disease_NN was_VBD 0_CD ._. 6786_CD ._. The_DT log_NN of_IN the_DT odds_NNS in_IN
          favor_NN of_IN this_DT event_NN was_VBD then_RB regressed_JJ on_IN age_NN using_VBG
          logistic_JJ regression_NN ._. Age_NNP was_VBD not_RB statistically_RB
          significant_JJ (_( i_NNP ._. e_SYM ._. ,_, Chi-square_NNP =_SYM 1_CD ._. 0237_CD ,_, p_NN =_SYM 0_CD ._. 3116_CD )_) ._. Age_NNP
          and_CC age-squared_JJ terms_NNS were_VBD also_RB fit_VB in_IN the_DT model_NN ,_, but_CC
          neither_DT was_VBD statistically_RB significant_JJ ._. Because_IN the_DT
          proportion_NN of_IN incidental_JJ detection_NN among_IN cases_NNS undergoing_VBG
          a_DT TURP_NNP was_VBD not_RB associated_VBN with_IN age_NN ,_, we_PRP multiplied_VBN in_IN each_DT
          age_NN category_NN for_IN each_DT year_NN 1985_CD through_IN 1997_CD the_DT
          proportion_NN 0_CD ._. 6786_CD by_IN the_DT total_JJ number_NN of_IN age-_NN and_CC
          year-specific_JJ TURPs_NNP recorded_VBD among_IN cases_NNS to_TO get_VB an_DT
          estimate_NN of_IN the_DT number_NN of_IN TURPs_NNP that_WDT led_VBD to_TO a_DT prostate_NN
          cancer_NN diagnosis_NN ._.
        
        
          1996_CD Utah_NNP Health_NNP Status_NNP Survey_NNP
          The_DT 1996_CD Utah_NNP Health_NNP Status_NNP Survey_NNP is_VBZ a_DT
          cross-sectional_JJ random_JJ survey_NN sponsored_VBN by_IN the_DT Utah_NNP
          Department_NNP of_IN Health_NNP ._. The_DT Gallup_NNP Organization_NNP collected_VBD
          the_DT data_NNS by_IN incorporating_VBG a_DT telephone_NN survey_NN instrument_NN
          into_IN a_DT computer-assisted_JJ ,_, random-digit-dialing_JJ software_NN
          program_NN called_VBD SURVENT_NNP ._. Supervised_NNP interviews_NNS were_VBD
          conducted_VBN across_IN twelve_CD local_JJ health_NN districts_NNS in_IN Utah_NNP by_IN
          trained_VBN interviewers_NNS ._. Although_IN the_DT survey_NN questionnaire_NN
          covered_VBD several_JJ topics_NNS ,_, we_PRP only_RB used_VBD data_NNS from_IN questions_NNS
          on_IN PSA_NNP screening_NN and_CC religious_JJ status_NN ._. The_DT interview_NN
          process_NN occurred_VBD during_IN June_NNP 1_CD through_IN August_NNP 31_CD ,_, 1996_CD ._.
          Interviews_NNS were_VBD conducted_VBN with_IN one_CD randomly_RB selected_VBN
          adult_NN aged_VBN 18_CD years_NNS or_CC older_JJR in_IN each_DT household_NN ._. If_IN
          required_VBN ,_, as_RB many_JJ as_IN nine_CD telephone_NN attempts_NNS were_VBD made_VBN to_TO
          contact_VB a_DT selected_VBN household_NN ._. The_DT response_NN rate_NN was_VBD
          66_CD ._. 3_LS %_NN ._. In_IN order_NN to_TO more_RBR accurately_RB generalize_VB the_DT survey_NN
          results_NNS to_TO the_DT Utah_NNP population_NN ,_, post-survey_JJ weighting_NN
          adjustments_NNS were_VBD made_VBN ._. Adjustments_NNP weighted_JJ the_DT sample_NN to_TO
          be_VB proportionally_RB consistent_JJ with_IN age_NN ,_, sex_NN ,_, geographic_JJ ,_,
          and_CC Hispanic_JJ status_NN distributions_NNS of_IN the_DT 1996_CD Utah_NNP
          population_NN ._.
        
        
          Statistical_NNP analysis_NN
          Age-adjusted_NNP prostate_NN cancer_NN incidence_NN rates_NNS were_VBD
          calculated_VBN for_IN individual_JJ calendar_NN years_NNS and_CC for_IN the_DT
          following_VBG year_NN groups_NNS :_: 1985_CD -_: 88_CD ,_, 1989_CD -_: 92_CD ,_, 1993_CD -_: 96_CD ,_, and_CC
          1997_CD -_: 99_CD ._. These_DT rates_NNS were_VBD calculated_VBN by_IN the_DT direct_JJ method_NN
          with_IN the_DT United_NNP States_NNPS standard_JJ population_NN for_IN the_DT year_NN
          2000_CD [_NN 13_CD ]_NN ._. Rates_NNS were_VBD calculated_VBN for_IN both_DT LDS_NNP and_CC
          nonLDS_NN populations_NNS in_IN Utah_NNP and_CC are_VBP expressed_VBN per_IN 100_CD ,_, 000_CD
          person-years_JJ ._. The_DT Member_NNP and_CC Statistical_NNP Records_NNP
          Department_NNP of_IN the_DT LDS_NNP Church_NNP provided_VBD annual_JJ age-_NN and_CC
          sex-specific_JJ estimates_NNS of_IN the_DT number_NN of_IN LDS_NNP Church_NNP
          members_NNS in_IN Utah_NNP (_( Larry_NNP Elkington_NNP ,_, Manager_NNP of_IN Church_NNP
          Management_NNP Information_NNP Center_NNP ,_, personal_JJ communication_NN )_) ._.
          Estimates_NNS for_IN the_DT nonLDS_NN population_NN of_IN Utah_NNP were_VBD derived_VBN
          by_IN subtracting_VBG the_DT number_NN of_IN LDS_NNP Church_NNP members_NNS from_IN the_DT
          Utah_NNP population_NN provided_VBN by_IN the_DT US_NNP Bureau_NNP of_IN the_DT Census_NNP [_NN
          14_CD ]_NN ._. Poisson_NNP regression_NN was_VBD used_VBN to_TO estimate_VB the_DT
          incidence_NN rate_NN ratio_NN between_IN LDS_NNP and_CC nonLDS_NN [_NN 15_CD ]_NN ._.
          Appropriate_NNP models_NNS reported_VBD below_IN were_VBD selected_VBN based_VBN on_IN
          the_DT deviance_NN goodness-of-fit_JJ test_NN ._. Analyses_NNS were_VBD
          performed_VBN with_IN standard_JJ packages_NNS of_IN the_DT Statistical_NNP
          Analysis_NNP System_NNP (_( SAS_NNP )_) [_NN 16_CD ]_NN ._.
        
      
      
        Results_NNS
        A_DT total_NN of_IN 14_CD ,_, 693_CD incident_NN cases_NNS of_IN histologically_RB
        confirmed_VBD invasive_JJ prostate_NN cancer_NN in_IN men_NNS aged_VBN 50_CD years_NNS and_CC
        older_JJR were_VBD diagnosed_VBN among_IN Utah_NNP residents_NNS during_IN the_DT period_NN
        1985_CD -_: 99_CD ._. Based_VBN on_IN linkage_NN with_IN LDS_NNP Church_NNP records_NNS ,_, 11_CD ,_, 291_CD
        (_( 76_CD ._. 8_CD %_NN )_) of_IN these_DT cases_NNS were_VBD determined_VBN to_TO be_VB LDS_NNP Church_NNP
        members_NNS ._. There_EX were_VBD 12_CD ,_, 088_CD (_( 82_CD ._. 3_LS %_NN )_) with_IN local_JJ /_NN regional_JJ
        stage_NN ,_, 1_CD ,_, 009_CD (_( 6_CD ._. 9_CD %_NN )_) with_IN distant_JJ stage_NN ,_, and_CC 1_CD ,_, 594_CD (_( 10_CD ._. 8_CD %_NN )_)
        with_IN unstaged_JJ prostate_NN cancer_NN ._. Two_CD cases_NNS had_VBD missing_VBG stage_NN
        information_NN ._.
        The_DT frequency_NN of_IN cases_NNS is_VBZ presented_VBN according_VBG to_TO
        religious_JJ preference_NN ,_, calendar_NN year_NN ,_, and_CC age_NN in_IN Table_NNP 1_CD ._.
        For_IN both_DT LDS_NNP and_CC nonLDS_NN ,_, a_DT shift_NN occurred_VBD over_IN time_NN from_IN
        cases_NNS being_VBG diagnosed_VBN at_IN older_JJR ages_NNS to_TO younger_JJR ages_NNS ._. For_IN
        the_DT first_JJ three_CD time_NN periods_NNS ,_, LDS_NNP compared_VBD with_IN nonLDS_NN
        cases_NNS were_VBD less_RBR likely_JJ to_TO be_VB diagnosed_VBN in_IN their_PRP$ 50_CD s_VBZ and_CC
        more_RBR likely_JJ to_TO be_VB diagnosed_VBN in_IN their_PRP$ 80_CD s_VBZ ._. The_DT frequency_NN of_IN
        cases_NNS is_VBZ also_RB presented_VBN according_VBG to_TO religious_JJ preference_NN ,_,
        calendar_NN year_NN ,_, and_CC stage_NN (_( Table_NNP 2_LS )_) ._. A_DT noticeable_JJ stage_NN
        shift_NN occurred_VBD from_IN distant_JJ to_TO local_JJ /_NN regional_JJ disease_NN over_IN
        time_NN for_IN both_DT LDS_NNP and_CC nonLDS_NN cases_NNS ._. Only_RB in_IN the_DT years_NNS 1989_CD
        through_IN 1992_CD do_VBP LDS_NNP cases_NNS have_VBP a_DT significantly_RB higher_JJR
        percentage_NN diagnosed_VBN with_IN local_JJ /_NN regional_JJ disease_NN ._.
        Local_JJ /_NN regional-staged_JJ TURP-_NNP and_CC nonTURP-detected_JJ
        age-adjusted_JJ prostate_NN cancer_NN incidence_NN rates_NNS for_IN men_NNS 50_CD
        years_NNS of_IN age_NN and_CC older_JJR in_IN Utah_NNP are_VBP presented_VBN according_VBG to_TO
        religious_JJ preference_NN and_CC calendar_NN year_NN (_( Figure_NN 1_LS )_) ._.
        NonTURP-detected_NNP prostate_NN cancer_NN incidence_NN rates_NNS are_VBP
        generally_RB higher_JJR for_IN LDS_NNP men_NNS across_IN the_DT years_NNS ,_, particularly_RB
        during_IN the_DT PSA-induced_NNP peak_NN ._. Despite_IN this_DT observation_NN ,_,
        TURP-detected_NNP prostate_NN cancer_NN incidence_NN rates_NNS are_VBP similar_JJ ._.
        Distant-staged_NNP age-adjusted_JJ prostate_NN cancer_NN incidence_NN rates_NNS
        for_IN men_NNS 50_CD years_NNS of_IN age_NN and_CC older_JJR in_IN Utah_NNP are_VBP also_RB
        presented_VBN by_IN religious_JJ preference_NN and_CC calendar_NN year_NN (_( Figure_NN
        2_LS )_) ._. These_DT rates_NNS are_VBP generally_RB similar_JJ ._.
        A_DT Poisson_NNP regression_NN model_NN ,_, adjusted_VBN for_IN age_NN and_CC stage_NN
        at_IN diagnosis_NN ,_, calendar_NN time_NN ,_, and_CC whether_IN prostate_NN cancer_NN
        was_VBD TURP-_NNP or_CC nonTURP-detected_JJ ,_, indicated_VBD that_IN LDS_NNP compared_VBD
        with_IN nonLDS_NN have_VBP 1_CD ._. 31_CD (_( 95_CD %_NN confidence_NN interval_NN ,_, 1_CD ._. 26_CD -_:
        1_CD ._. 36_CD )_) times_NNS the_DT incidence_NN rate_NN of_IN prostate_NN cancer_NN among_IN men_NNS
        aged_VBN 50_CD years_NNS and_CC older_JJR in_IN Utah_NNP ._. The_DT adjusted_VBN Poisson_NNP
        regression_NN model_NN gave_VBD rate_NN ratios_NNS of_IN LDS_NNP to_TO nonLDS_NN of_IN 2_CD ._. 18_CD
        (_( 1_CD ._. 99_CD -_: 2_CD ._. 40_CD )_) in_IN 1985_CD -_: 88_CD ,_, 1_CD ._. 20_CD (_( 1_CD ._. 12_CD -_: 1_CD ._. 29_CD )_) in_IN 1989_CD -_: 92_CD ,_,
        1_CD ._. 15_CD (_( 1_CD ._. 08_CD -_: 1_CD ._. 24_CD )_) in_IN 1993_CD -_: 1996_CD ,_, and_CC 1_CD ._. 13_CD (_( 1_CD ._. 04_CD -_: 1_CD ._. 22_CD )_) in_IN
        1997_CD -_: 99_CD ._. Adjusted_NNP rate_NN ratios_NNS also_RB indicated_VBD significantly_RB
        higher_JJR rates_NNS for_IN LDS_NNP compared_VBD with_IN nonLDS_NN for_IN each_DT age_NN
        group_NN [_NN 1_CD ._. 13_CD (_( 1_CD ._. 01_CD -_: 1_CD ._. 27_CD )_) in_IN ages_NNS 50_CD -_: 59_CD ,_, 1_CD ._. 48_CD (_( 1_CD ._. 38_CD -_: 1_CD ._. 58_CD )_) in_IN
        ages_NNS 60_CD -_: 69_CD ,_, 1_CD ._. 28_CD (_( 1_CD ._. 21_CD -_: 1_CD ._. 36_CD )_) in_IN ages_NNS 70_CD -_: 79_CD ,_, and_CC 1_CD ._. 16_CD
        (_( 1_CD ._. 04_CD -_: 1_CD ._. 28_CD )_) in_IN ages_NNS 80_CD and_CC older_JJR ]_NN and_CC for_IN certain_JJ stage_NN
        categories_NNS [_NN 1_CD ._. 36_CD (_( 1_CD ._. 31_CD -_: 1_CD ._. 43_CD )_) in_IN local_JJ /_NN regional_JJ stage_NN ,_, 0_CD ._. 97_CD
        (_( 0_CD ._. 84_CD -_: 1_CD ._. 11_CD )_) in_IN distant_JJ stage_NN ,_, and_CC 1_CD ._. 17_CD (_( 1_CD ._. 04_CD -_: 1_CD ._. 31_CD )_) in_IN
        unstaged_JJ ]_NN ._.
        Finally_RB ,_, on_IN the_DT basis_NN of_IN the_DT 1996_CD Utah_NNP Health_NNP Status_NNP
        Survey_NNP ,_, LDS_NNP men_NNS compared_VBN with_IN nonLDS_NN men_NNS were_VBD more_RBR likely_JJ
        to_TO have_VB received_VBN a_DT PSA_NNP screen_NN in_IN the_DT previous_JJ year_NN (_( Table_NNP
        3_LS )_) ._.
      
      
        Discussion_NNP
        Evidence_NN that_DT prostate_NN cancer_NN incidence_NN rates_NNS are_VBP
        sensitive_JJ to_TO screening_NN is_VBZ well_RB established_VBN [_NN 2_CD 3_CD 17_CD 18_CD 19_CD
        20_CD ]_NN ._. Potosky_NNP 
        et_CC al_NN ._. examined_VBD the_DT potential_JJ
        influence_NN that_DT adoption_NN of_IN transrectal_NN ultrasound_NN (_( TRUS_NNP )_)
        and_CC PSA_NNP testing_NN had_VBD on_IN increasing_VBG prostate_NN needle_NN biopsy_NN
        rates_NNS in_IN the_DT SEER_NNP areas_NNS from_IN 1986_CD through_IN 1991_CD [_NN 17_CD ]_NN ._.
        Both_DT TRUS_NNP and_CC PSA_NNP testing_NN rates_NNS ,_, initially_RB near_IN zero_CD ,_,
        increased_VBN to_TO almost_RB 2_CD ,_, 000_CD and_CC 20_CD ,_, 000_CD per_IN 100_CD ,_, 000_CD ,_,
        respectively_RB ._. Their_PRP$ study_NN further_RBR showed_VBD a_DT correlation_NN
        between_IN increasing_VBG needle_NN biopsy_NN rates_NNS and_CC prostate_NN cancer_NN
        incidence_NN rates_NNS ._. Legler_NNP 
        et_CC al_NN ._. added_VBD to_TO our_PRP$ understanding_NN of_IN
        the_DT role_NN of_IN PSA_NNP testing_NN on_IN prostate_NN cancer_NN incidence_NN rates_NNS
        by_IN showing_VBG that_IN first_JJ time_NN PSA_NNP testing_NN proportions_NNS ,_, not_RB the_DT
        overall_JJ PSA_NNP proportion_NN ,_, track_NN closely_RB with_IN prostate_NN cancer_NN
        incidence_NN rates_NNS [_NN 20_CD ]_NN ._. In_IN a_DT comparison_NN of_IN prostate_NN cancer_NN
        incidence_NN rates_NNS among_IN white_JJ men_NNS in_IN five_CD of_IN the_DT SEER_NNP areas_NNS
        (_( Detroit_NNP ,_, Utah_NNP ,_, Seattle-_NNP Puget_NNP Sound_NNP ,_, Iowa_NNP ,_, and_CC
        Connecticut_NNP )_) ,_, Brawley_NNP showed_VBD that_IN the_DT rates_NNS were_VBD highest_JJS in_IN
        Seattle_NNP from_IN 1986_CD through_IN 1991_CD ,_, but_CC then_RB highest_JJS in_IN Utah_NNP
        from_IN 1992_CD through_IN 1994_CD [_NN 21_CD ]_NN ._. In_IN a_DT consistent_JJ manner_NN ,_, the_DT
        proportion_NN of_IN men_NNS receiving_VBG a_DT first_JJ time_NN PSA_NNP tended_VBD to_TO be_VB
        highest_JJS in_IN Seattle_NNP in_IN the_DT earlier_JJR years_NNS but_CC highest_JJS in_IN Utah_NNP
        in_IN the_DT later_JJ years_NNS [_NN 20_CD ]_NN ._. Because_IN 76_CD ._. 8_CD %_NN of_IN diagnosed_VBN
        prostate_NN cancer_NN cases_NNS in_IN Utah_NNP during_IN our_PRP$ study_NN period_NN were_VBD
        in_IN LDS_NNP men_NNS ,_, we_PRP may_MD assume_VB that_IN the_DT relatively_RB high_JJ
        proportion_NN of_IN first_JJ time_NN PSA_NNP tests_NNS in_IN Utah_NNP primarily_RB
        reflects_VBZ LDS_NNP men_NNS ._.
        The_DT results_NNS ,_, based_VBN on_IN Poisson_NNP regression_NN ,_, indicate_VBP that_IN
        LDS_NNP men_NNS compared_VBN with_IN nonLDS_NN men_NNS residing_VBG in_IN Utah_NNP ,_, after_IN
        adjusting_VBG for_IN age_NN and_CC stage_NN at_IN diagnosis_NN ,_, calendar_NN time_NN and_CC
        TURP_NNP experienced_VBD significantly_RB higher_JJR prostate_NN cancer_NN
        incidence_NN rates_NNS ._. Unfortunately_RB ,_, our_PRP$ broad_JJ stage_NN categories_NNS
        limited_JJ our_PRP$ ability_NN to_TO adjust_VB for_IN this_DT variable_JJ such_JJ that_IN
        differences_NNS in_IN stage_NN could_MD still_RB be_VB explaining_VBG some_DT of_IN the_DT
        higher_JJR incidence_NN among_IN LDS_NNP men_NNS ._. Nevertheless_RB ,_, the_DT higher_JJR
        rates_NNS among_IN LDS_NNP men_NNS could_MD be_VB because_IN they_PRP more_RBR readily_RB
        adopted_VBN TRUS_NNP and_CC digital_JJ rectal_NN exams_NNS in_IN the_DT first_JJ time_NN
        period_NN ,_, prior_RB to_TO widespread_JJ PSA_NNP screening_NN ,_, and_CC then_RB more_RBR
        readily_RB adopted_VBN PSA_NNP screening_NN but_CC to_TO a_DT lesser_JJR degree_NN ._.
        Historically_NNP ,_, physicians_NNS have_VBP used_VBN digital_JJ rectal_NN
        examinations_NNS in_IN early_JJ detection_NN efforts_NNS [_NN 22_CD 23_CD ]_NN ._. In_IN
        general_JJ ,_, digital_JJ rectal_NN examination_NN has_VBZ a_DT 1_CD -_: 2_CD %_NN detection_NN
        rate_NN and_CC the_DT PSA_NNP test_NN ,_, which_WDT is_VBZ relatively_RB easy_JJ to_TO perform_VB ,_,
        has_VBZ a_DT 3_CD %_NN detection_NN rate_NN in_IN men_NNS who_WP are_VBP older_JJR than_IN 50_CD years_NNS
        of_IN age_NN [_NN 24_CD ]_NN ._.
        Screening_NNP is_VBZ further_RBR implicated_VBN by_IN the_DT fact_NN that_IN the_DT
        higher_JJR rate_NN ratios_NNS of_IN LDS_NNP to_TO nonLDS_NN prostate_NN cancer_NN
        incidence_NN occur_VB in_IN local_JJ /_NN regional_JJ stage_NN cases_NNS ._. Age-_NNP and_CC
        stage-shifts_JJ in_IN the_DT data_NNS are_VBP also_RB consistent_JJ with_IN higher_JJR
        levels_NNS of_IN screening_NN among_IN LDS_NNP men_NNS ._. Unfortunately_RB ,_, there_EX is_VBZ
        little_JJ screening_VBG data_NNS available_JJ to_TO allow_VB us_PRP to_TO directly_RB
        evaluate_VB the_DT role_NN screening_NN plays_VBZ in_IN the_DT higher_JJR prostate_NN
        cancer_NN incidence_NN rates_NNS observed_VBD among_IN LDS_NNP men_NNS ._.
        Nevertheless_RB ,_, based_VBN on_IN the_DT 1996_CD Utah_NNP Health_NNP Status_NNP Survey_NNP
        we_PRP showed_VBD that_IN LDS_NNP men_NNS compared_VBN with_IN nonLDS_NN men_NNS were_VBD more_RBR
        likely_JJ to_TO have_VB received_VBN a_DT PSA_NNP test_NN in_IN the_DT past_JJ year_NN ,_,
        overall_JJ and_CC within_IN age_NN categories_NNS ._. Yet_RB the_DT order_NN of_IN PSA_NNP
        received_VBD ,_, whether_IN a_DT first_JJ or_CC subsequent_JJ PSA_NNP test_NN ,_, is_VBZ
        unknown_JJ ._. In_IN addition_NN ,_, we_PRP do_VBP not_RB know_VB whether_IN higher_JJR PSA_NNP
        screening_NN use_NN among_IN LDS_NNP men_NNS remained_VBD higher_JJR prior_RB to_TO or_CC
        after_IN 1996_CD ._.
        Studies_NNS have_VBP shown_VBN that_IN men_NNS undergoing_VBG PSA_NNP screening_VBG are_VBP
        more_RBR likely_JJ to_TO display_VB an_DT overall_JJ constellation_NN of_IN
        health-promoting_JJ behavior_NN ,_, such_JJ as_IN not_RB smoking_VBG and_CC seeking_VBG
        health_NN care_NN regularly_RB [_NN 25_CD 26_CD ]_NN ._. Smokers_NNS are_VBP less_RBR likely_JJ
        to_TO use_VB medical_JJ services_NNS [_NN 27_CD 28_CD ]_NN ,_, with_IN one_CD study_NN finding_VBG
        that_IN 76_CD %_NN of_IN nonsmokers_NNS compared_VBN with_IN 64_CD %_NN of_IN smokers_NNS
        receiving_VBG regular_JJ checkups_NNS [_NN 26_CD ]_NN ._. Utah_NNP has_VBZ historically_RB
        experienced_VBN the_DT lowest_JJS smoking_NN prevalence_NN in_IN the_DT United_NNP
        States_NNPS [_NN 29_CD ]_NN ._. Utah_NNP smoking_NN prevalence_NN is_VBZ currently_RB
        closest_JJS to_TO the_DT 
        Healthy_JJ People_NNS 2010_CD goal_NN for_IN the_DT
        nation_NN of_IN 12_CD %_NN [_NN 30_CD ]_NN ,_, with_IN smoking_NN prevalence_NN in_IN the_DT year_NN
        2000_CD of_IN 12_CD ._. 9_CD %_NN compared_VBN with_IN the_DT next_JJ lowest_JJS prevalence_NN in_IN
        California_NNP of_IN 17_CD ._. 2_LS and_CC nationally_RB of_IN 23_CD ._. 2_LS %_NN [_NN 31_CD ]_NN ._. This_DT
        low_JJ smoking_NN prevalence_NN is_VBZ primarily_RB explained_VBN by_IN the_DT over_JJ
        70_CD %_NN LDS_NNP population_NN who_WP attend_VBP church_NN weekly_JJ ,_, among_IN which_WDT
        less_JJR than_IN 1_CD %_NN are_VBP current_JJ smokers_NNS [_NN 5_CD ]_NN ._. Men_NN who_WP are_VBP
        married_VBN and_CC who_WP have_VBP medical_JJ insurance_NN have_VBP the_DT highest_JJS
        levels_NNS of_IN PSA_NNP use_NN in_IN Utah_NNP [_NN 25_CD ]_NN ._. According_VBG to_TO the_DT 1996_CD
        Utah_NNP Health_NNP Status_NNP Survey_NNP ,_, 74_CD ._. 7_CD %_NN of_IN LDS_NNP men_NNS and_CC 58_CD ._. 9_CD %_NN of_IN
        nonLDS_NN men_NNS in_IN Utah_NNP were_VBD married_VBN ,_, and_CC 92_CD ._. 2_LS %_NN of_IN LDS_NNP men_NNS
        compared_VBN with_IN 86_CD ._. 2_LS %_NN of_IN nonLDS_NN men_NNS were_VBD medically_RB insured_VBN [_NN
        32_CD ]_NN ._.
        In_IN a_DT consistent_JJ manner_NN ,_, studies_NNS have_VBP found_VBN that_IN men_NNS who_WP
        are_VBP generally_RB healthier_JJR [_NN 26_CD 33_CD ]_NN ,_, married_VBN [_NN 34_CD 35_CD ]_NN ,_, and_CC
        more_RBR educated_VBN [_NN 35_CD 36_CD ]_NN are_VBP more_RBR likely_JJ to_TO be_VB diagnosed_VBN
        with_IN prostate_NN cancer_NN than_IN men_NNS with_IN different_JJ
        characteristics_NNS ._. Yet_RB these_DT men_NNS also_RB tend_VBP to_TO experience_VB
        better_JJR survival_NN [_NN 35_CD 37_CD 38_CD 39_CD ]_NN ,_, indicating_VBG that_IN they_PRP are_VBP
        possibly_RB being_VBG diagnosed_VBN at_IN earlier_JJR stages_NNS because_IN of_IN more_RBR
        aggressive_JJ screening_NN ._. In_IN addition_NN to_TO LDS_NNP having_VBG
        comparatively_RB low_JJ smoking_NN prevalence_NN ,_, a_DT higher_JJR proportion_NN
        who_WP are_VBP married_VBN ,_, and_CC a_DT higher_JJR proportion_NN who_WP are_VBP medically_RB
        insured_VBN ,_, 95_CD %_NN of_IN LDS_NNP men_NNS compared_VBN with_IN 89_CD %_NN of_IN nonLDS_NN men_NNS
        reported_VBD having_VBG at_IN least_JJS a_DT high_JJ school_NN education_NN ,_, according_VBG
        to_TO the_DT 1996_CD Health_NNP Status_NNP Survey_NNP [_NN 32_CD ]_NN ._.
        In_IN our_PRP$ study_NN ,_, adjusting_VBG for_IN TURP-detected_NNP cases_NNS allowed_VBD
        us_PRP to_TO better_JJR assess_VB the_DT influence_NN of_IN screening_NN on_IN prostate_NN
        cancer_NN incidence_NN trends_NNS ._. Frequent_JJ use_NN of_IN TURP_NNP for_IN benign_JJ
        prostatic_JJ hyperplasia_NN in_IN the_DT 1970_CD s_VBZ and_CC 1980_CD s_VBZ and_CC the_DT rapid_JJ
        introduction_NN and_CC widespread_JJ adoption_NN of_IN PSA_NNP screening_NN
        beginning_VBG in_IN the_DT late_JJ 1980_CD s_VBZ ,_, tapped_VBN an_DT extensive_JJ pool_NN of_IN
        latent_NN and_CC preclinical_JJ prostate_NN disease_NN [_NN 40_CD 41_CD ]_NN ._.
        Consistent_NNP with_IN another_DT study_NN ,_, we_PRP found_VBD that_IN in_IN the_DT mid_JJ
        1980_CD s_VBZ up_IN to_TO 50_CD %_NN or_CC more_JJR of_IN all_DT prostate_NN cancer_NN cases_NNS were_VBD
        incidentally_RB detected_VBN through_IN TURPs_NNP [_NN 41_CD ]_NN ._. However_RB ,_, as_IN
        medications_NNS with_IN few_JJ side_NN effects_NNS became_VBD available_JJ to_TO treat_VB
        benign_JJ prostatic_JJ hypterplasia_NN and_CC PSA_NNP screening_NN became_VBD
        widely_RB adopted_VBN ,_, TURP-detected_NNP cases_NNS declined_VBD from_IN their_PRP$
        peak_NN in_IN 1987_CD through_IN 1993_CD [_NN 41_CD ]_NN ._. Our_PRP$ results_NNS showed_VBD a_DT
        similar_JJ decline_NN in_IN the_DT TURP-detected_NNP prostate_NN cancer_NN
        incidence_NN rates_NNS ,_, followed_VBN by_IN a_DT leveling_VBG off_RP between_IN 1994_CD
        and_CC 1999_CD ,_, for_IN both_DT LDS_NNP and_CC nonLDS_NN cases_NNS in_IN Utah_NNP ._. We_PRP also_RB
        found_VBD the_DT level_NN of_IN TURP-detected_NNP rates_NNS to_TO be_VB very_RB similar_JJ
        between_IN LDS_NNP and_CC nonLDS_NN ._.
        Data_NNP are_VBP not_RB available_JJ to_TO identify_VB whether_IN TURP_NNP rates_NNS
        differed_VBD between_IN LDS_NNP and_CC nonLDS_NN ._. However_RB ,_, if_IN we_PRP assume_VBP they_PRP
        were_VBD similar_JJ or_CC even_RB higher_JJR among_IN LDS_NNP ,_, and_CC given_VBN the_DT
        similar_JJ TURP-detected_NNP prostate_NN cancer_NN incidence_NN rates_NNS
        observed_VBD ,_, there_EX is_VBZ no_DT reason_NN to_TO believe_VB that_DT prostate_NN
        cancer_NN is_VBZ more_RBR common_JJ in_IN LDS_NNP men_NNS ._. Indeed_RB ,_, an_DT older_JJR study_NN
        based_VBN on_IN Utah_NNP data_NNS covering_VBG the_DT years_NNS 1971_CD through_IN 1985_CD
        found_VBD that_IN the_DT age-adjusted_JJ (_( to_TO the_DT 1970_CD US_NNP standard_JJ )_)
        prostate_NN cancer_NN incidence_NN rates_NNS per_IN 100_CD ,_, 000_CD person-years_JJ
        were_VBD 76_CD ._. 3_LS for_IN LDS_NNP compared_VBD with_IN 109_CD ._. 1_LS for_IN nonLDS_NN [_NN 42_CD ]_NN
        ._.
        One_CD goal_NN of_IN screening_NN is_VBZ to_TO identify_VB the_DT presence_NN of_IN
        disease_NN before_IN it_PRP becomes_VBZ clinically_RB evident_JJ ._. If_IN PSA-based_NNP
        screening_NN achieved_VBD this_DT goal_NN ,_, we_PRP would_MD anticipate_VB dramatic_JJ
        increases_NNS in_IN the_DT number_NN of_IN cases_NNS diagnosed_VBN with_IN early_JJ stage_NN
        prostate_NN cancer_NN ._. The_DT available_JJ data_NN did_VBD not_RB allow_VB us_PRP to_TO
        restrict_VB our_PRP$ analyses_NNS to_TO cases_NNS with_IN just_RB localized_JJ disease_NN ._.
        Results_NNS from_IN previous_JJ studies_NNS have_VBP demonstrated_VBN that_DT choice_NN
        of_IN therapy_NN for_IN prostate_NN cancer_NN may_MD influence_VB subsequent_JJ
        determination_NN of_IN staging_NN ._. Specifically_RB ,_, many_JJ patients_NNS that_WDT
        clinically_RB appeared_VBD to_TO have_VB localized_JJ disease_NN were_VBD
        determined_VBN to_TO have_VB regional_JJ stage_NN disease_NN based_VBN on_IN
        pathological_JJ review_NN of_IN tissue_NN that_WDT was_VBD obtained_VBN from_IN
        radical_JJ prostatectomy_NN [_NN 43_CD 44_CD ]_NN ._. Similar_JJ patients_NNS that_WDT did_VBD
        not_RB undergo_VB aggressive_JJ surgical_JJ treatment_NN would_MD not_RB have_VB
        had_VBN the_DT opportunity_NN for_IN a_DT comparable_JJ evaluation_NN of_IN stage_NN ;_:
        the_DT latter_JJ group_NN of_IN patients_NNS would_MD have_VB remained_VBN classified_VBN
        with_IN localized_JJ disease_NN ._. Therefore_RB ,_, it_PRP was_VBD not_RB possible_JJ in_IN
        these_DT data_NNS to_TO distinguish_VB between_IN cases_NNS with_IN true_JJ localized_JJ
        disease_NN and_CC those_DT who_WP received_VBD a_DT clinical_JJ diagnosis_NN of_IN
        localized_JJ disease_NN but_CC actually_RB had_VBD undetected_JJ regional_JJ
        stage_NN disease_NN ._. Hence_RB ,_, cases_NNS of_IN local_JJ and_CC regional_JJ stage_NN
        disease_NN were_VBD combined_VBN in_IN the_DT present_JJ study_NN ._.
      
      
        Conclusion_NNP
        LDS_NNP men_NNS compared_VBN with_IN nonLDS_NN men_NNS may_MD have_VB adopted_VBN
        digital_JJ rectal_NN and_CC PSA_NNP screening_VBG more_RBR readily_RB ._. Higher_JJR PSA_NNP
        screening_NN was_VBD observed_VBN among_IN LDS_NNP ,_, both_DT overall_JJ and_CC within_IN
        selected_VBN age_NN groups_NNS according_VBG to_TO the_DT 1996_CD Utah_NNP Health_NNP
        Status_NNP Survey_NNP ._. In_IN addition_NN ,_, individuals_NNS in_IN the_DT LDS_NNP Church_NNP
        tend_VBP to_TO reflect_VB a_DT host_NN of_IN characteristics_NNS (_( i_NNP ._. e_SYM ._. ,_, low_JJ
        smoking_NN prevalence_NN ,_, a_DT high_JJ proportion_NN married_VBD ,_, a_DT high_JJ
        proportion_NN medically_RB insured_VBD ,_, and_CC a_DT high_JJ level_NN of_IN
        education_NN )_) that_WDT are_VBP associated_VBN with_IN good_JJ general_JJ health_NN ._.
        Previous_JJ studies_NNS have_VBP indicated_VBN that_IN these_DT characteristics_NNS
        are_VBP associated_VBN with_IN more_RBR aggressive_JJ PSA_NNP screening_NN and_CC ,_,
        because_IN of_IN the_DT high_JJ prevalence_NN of_IN asymptomatic_JJ prostate_NN
        cancer_NN in_IN the_DT population_NN ,_, subsequent_JJ prostate_NN cancer_NN
        diagnosis_NN ._. If_IN LDS_NNP men_NNS adopted_VBD screening_VBG more_RBR readily_RB ,_, we_PRP
        may_MD expect_VB that_IN they_PRP would_MD have_VB experienced_VBN higher_JJR prostate_NN
        cancer_NN incidence_NN rates_NNS ._. Evidence_NN in_IN this_DT paper_NN indicates_VBZ
        that_IN the_DT comparatively_RB high_JJ prostate_NN cancer_NN incidence_NN rates_NNS
        in_IN Utah_NNP are_VBP likely_JJ due_NN to_TO ,_, at_IN least_JJS in_IN part_NN ,_, more_RBR
        aggressive_JJ screening_NN among_IN LDS_NNP ._.
      
    
  
